Fiona Cai

Fiona Cai is a Vice President at Long Hill Capital (长岭资本), a China-focused, thesis-driven venture capital firm founded in 2016. Her firm email ([hidden]) is confirmed against the Long Hill Capital domain, and her stated title is Vice President. Beyond this, Ms. Cai keeps a minimal public profile: Chinese and English team listings for Long Hill (which name figures such as founder Xiaodong Jiang, partner Bo Jiang, finance VP Zhenting Wang, investment director Hangcheng Sun, and investment VPs Song Mei and Xuehao Xie) do not surface a detailed public biography, education history, or photograph for her. The details below are therefore presented at the firm level, which is what public sources reliably support.

Long Hill Capital was established by the team that led the China investing practice for New Enterprise Associates (NEA), one of the largest U.S. venture firms, from 2005 to 2015 — a period in which they reported over US$500 million in realized returns. The broader team draws experience from firms including NEA, Matrix Partners China, Morningside VC, and Matrix. The firm is headquartered in Shanghai with an additional office in Beijing.

The firm has scaled quickly across three funds: a debut US$125M Fund I (2016), an oversubscribed US$265M Fund II (2018), and a US$300M+ Fund III (closed March 2021), bringing total committed capital to roughly US$800M (reported at various points as 3.5–6 billion RMB). Its investment thesis has evolved from "technology-enabled healthcare and consumer services" toward a sharper focus on healthcare and longevity — framed by the firm as making "longevity a gift of life for every Chinese."

As a Vice President, Ms. Cai sits in the investment-professional tier of the firm (below Partner/Managing Partner), a role that at a fund of this size typically covers deal sourcing, diligence, and portfolio support within Long Hill's core healthcare and/or consumer verticals.

*(Firm-level; individual deal attribution to Ms. Cai could not be verified.)*

• Thesis-driven, early-stage investing in China — the firm describes itself as "a next-generation, thesis-driven venture capital firm."
• Two core verticals: (1) technology-enabled healthcare and longevity services, and (2) technology-enabled consumer services.
• Stated mission: to pursue "technology-enabled transformations of the healthcare and longevity sectors" and "massively improve health and quality of life for every Chinese."
• Stage/check: early-stage entry (seed/Series A) with capacity to follow on into later rounds out of ~US$800M in cumulative AUM; specific per-deal check sizes are not publicly disclosed.
• Geography: exclusively China-focused.